Bowles IE, Orellana EA. Rethinking RNA Modifications: Therapeutic Strategies for Targeting Dysregulated RNA. J Mol Biol. 2025 Mar 7:169046. doi: 10.1016/j.jmb.2025.169046. Epub ahead of print. PMID: 40057447.
Publications
All Publications
A methyltransferase-independent role for METTL1 in tRNA aminoacylation and oncogenic transformation
Ali RH, Orellana EA, Lee SH, Chae YC, Chen Y, Clauwaert J, Kennedy AL, Gutierrez AE, Papke DJ, Valenzuela M, Silverman B, Falzetta A, Ficarro SB, Marto JA, Fletcher CDM, Perez-Atayde A, Alcindor T, Shimamura A, Prensner JR, Gregory RI, Gutierrez A. A...
Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent
Abdelaal AM, Sohal IS, Iyer SG, Sudarshan K, Orellana EA, Ozcan KE, Dos Santos AP, Low PS, Kasinski AL. Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent. Mol Ther Nucleic Acids. 2024 Apr...
How Cancer Cells Hijack Protein Production to Grow Quickly
Orellana, EA, Gregory, RI. 2023. Frontiers for Young Minds.
Structural basis of regulated m7G tRNA modification by METTL1-WDR4
Authors: Li J, Wang L, Hahn Q, Nowak RP, Viennet T, Orellana EA, et al.(2023). Nature. Jan;613(7943):391-397. doi: 10.1038/s41586-022-05566-4. Epub 2023 Jan 4. PMID: 36599985.
tRNA dysregulation and disease
Orellana, E.A., Siegal, E., and Gregory, R.I. (2022). Nat Rev Genet. PMID: 35681060
METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation.
Orellana, E.A., et al. (2021). Mol Cell 81, 3323-3338.e3314. PMID: 34352207
METTL4 is an snRNA m6Am methyltransferase that regulates RNA splicing
Chen, H., Gu, L., Orellana, E.A., et al. (2020). Cell Res 30, 544-547. PMID: 31913360
Identification and validation of microRNAs that synergize with miR-34a – a basis for combinatorial microRNA therapeutics
Orellana, E.A., et al. (2019). Cell Cycle 18, 1798-1811. PMID: 31258013
Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias
Hinze, L., Pfirrmann, M., Karim, S., Degar, J., McGuckin, C., Vinjamur, D., Sacher, J., Stevenson, K.E., Neuberg, D.S., Orellana, E., et al. (2019). Cancer Cell 35, 664-676.e667. PMID: 30991026
Enhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin
Orellana, E.A., et al. (2019). Mol Ther Nucleic Acids 16, 505-518. PMID: 31071527
New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K(+)/H(+) Exchange
Rangasamy, L., Chelvam, V., Kanduluru, A.K., Srinivasarao, M., Bandara, N.A., You, F., Orellana, E.A., et al. (2018). Bioconjug Chem 29, 1047-1059. PMID: 29446616
FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer
Orellana, E.A., Tenneti, S., Rangasamy, L., Lyle, L.T., Low, P.S., and Kasinski, A.L. Sci Transl Med 9. PMID: 28768807
Sulforhodamine B (SRB) Assay in Cell Culture to Investigate Cell Proliferation
Orellana, E.A., and Kasinski, A.L. (2016). Bio Protoc 6. PMID: 28573164
MicroRNAs in Cancer: A Historical Perspective on the Path from Discovery to Therapy
Orellana, E.A., and Kasinski, A.L. (2015). Cancers (Basel) 7, 1388-1405. PMID: 26226002
A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer
Kasinski, A.L., Kelnar, K., Stahlhut, C., Orellana, E., Zhao, J., Shimer, E., Dysart, S., Chen, X., Bader, A.G., and Slack, F.J. Oncogene 34, 3547-3555. PMID: 25174400